This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tekla Life Sciences Investors Insider Bought Shares Worth $125,116, According to a Recent SEC Filing MT
Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund and Tekla Healthcare Investors Approves Election of Rose Dimartino, C. William Maher, Todd Reit and Stephen Bird as New Trustees CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 29, 2023 CI
Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2023 CI
Tekla Life Sciences Investors Declares Distribution, Payable on June 30, 2023 CI
Tekla Life Sciences Investors announces an Equity Buyback for 12% of its outstanding shares. CI
Tekla Life Sciences Investors authorizes a Buyback Plan. CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2023 CI
Tekla Life Sciences Investors Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Tekla Life Sciences Investors Declares Distribution, Payable on December 30, 2022 CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 30, 2022 CI
Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2022 CI
Tekla Life Sciences Cuts Quarterly Dividend to $0.35 a Share From $0.39, Payable June 30 to Shareholders as of May 27 MT
Tekla Life Sciences Investors Declares a Distribution, Payable on June 30, 2022 CI
Sector Update: Financial Stocks Adding to Tuesday Gains Just Ahead of Closing Bell MT
Sector Update: Financial MT
Tekla Life Sciences Investors Renews Share Repurchase Program MT
Tekla Life Sciences Investors authorizes a Buyback Plan. CI
Tekla Life Sciences Investors announces an Equity Buyback for 12% of its outstanding shares. CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2022 CI
Tekla Life Sciences Investors Reports Earnings Results for the Full Year Ended September 30, 2021 CI
Tekla Life Sciences Investors Declares Distribution, Payable on December 31, 2021 CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 30, 2021 CI
Tekla Life Sciences Investors Declares Stock Distribution, Payable on June 30, 2021 CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2021 CI
Chart Abrdn Life Sciences Investors
More charts
abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.
More about the company
  1. Stock Market
  2. Equities
  3. HQL Stock
  4. News Abrdn Life Sciences Investors
  5. Tekla Life Sciences Investors Insider Bought Shares Worth $125,116, According to a Recent SEC Filing